Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
MaxCyte, Inc.
MaxCyte to present on development of novel tumor-targeted enhanced potency T cell immunotherapy at the 15th Annual Meeting of the International Society of Cellular Therapy ISCT
May 19th, 2009
MaxCyte will be presenting results on the development of an engineered tumor-targeted T cell therapy uniquely enabled by the use of MaxCyte® GT™ Flow Transfection System at the 15th Annual Meeting of the International Society of Cellular Therapy (ISCT) in San Diego. The presentation is entitled "Scalable electroporation mediates efficient RNA-CAR transfection in expanded T cells with a dependence of expression duration on intracellular activation domains" and will be presented as Poster #87 on May 5, 2009 at 5:00-6:00PM. This study described in the presentation investigated the development of safe, robust, clinical scale, cGMP and regulatory-compliant process for...
Source: Cancer Weekly (2009-05-19)
|
